Telbivudine versus Lamivudine
Globe Study: 52 Weeks
Telbivudine versus Lamivudine
Globe Study: Design

Globe: Key Study Features
• Randomized, double-blinded
• HBeAg-positive (n = 921)
• HBeAg-negative (n = 446)
• Treatment-naïve
• HBV DNA >10^6 copies/mL

Week 0
Randomized

Telbivudine: 600 mg/day
(n = 683)

Lamivudine: 100 mg/day
(n = 687)

Week 52
Analysis

Telbivudine versus Lamivudine
Globe Study: Results

HBeAg-POSITIVE Patients: Week 52 Treatment Response

Telbivudine versus Lamivudine
Globe Study: Results

HBeAg-NEGATIVE Patients: Week 52 Treatment Response

Conclusions: “Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic and histologic response at 1 year were significantly higher in patients treated with telbivudine than in patients treated with lamivudine. In both the HBeAg-negative and the HBeAg-positive groups, telbivudine demonstrated greater HBV DNA suppression with less resistance than did lamivudine.”